Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
VRVertex Pharmaceuticals Incorporated logo

Vertex Pharmaceuticals Incorporated (VRTX)

NASDAQ Global Select · Currency in USD
$523.93 ▼ -11.24 (-2.10%)
At close: Oct 23, 4:00 PM ET. Market closed.
$525.00 ▲ +1.07 (+0.20%)
After hours: Oct 23, 7:46 PM ET

Summary

Previous Close
$535.17
Open
$531.11
Day's Range
$522.92 – $532.99
52 Week Range
$403.16 – $560.25
Volume
832,628
Avg. Volume
1,379,876
Market Cap
$132.80B
Beta (5Y Monthly)
0.32
PE Ratio (TTM)
30.25
EPS (TTM)
$17.35
Earnings Date
Nov 2, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$573.50

Profile: Vertex Pharmaceuticals Incorporated

Sector
Healthcare
Industry
Biotechnology
Full-time employees
6,400
CEO
Reshma Kewalramani
Website
vrtx.com

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation.

Earnings

Next report: Mon, Nov 2, 2026
EPS estimate $4.80 · Revenue est. $3.42B
DateEst.Actual
Aug 3, 2026$4.74$4.73Miss
May 4, 2026$4.24$4.47Beat
Feb 12, 2026$5.11$5.03Miss
Nov 3, 2025$4.57$4.80Beat
Aug 4, 2025$4.29$4.52Beat
May 5, 2025$4.25$4.06Miss

Analyst view

Consensus price target
$573.50 ▲ +9.5%
Range $350.00 – $665.00
Rating: Buy
Buy 86% · Hold 13% · Sell 2%

Get free alerts on VRTX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.